- John Laing Environmental Assets Group (JLEN) has announced the appointment of Hans Joern Rieks as a non-executive director of the company, commencing 13 June 2019.
- LXi REIT (LXI), the specialist inflation-protected very long income REIT, has reported annual results for the year ended 31 March 2019. LXI’s leases are typically 20 to 30 years to expiry or first break. The company had a strong year with total returns NAV and total shareholder returns up 12.1% and 30.7%. We note that as of May 13 this year, LXI’s shares were trading at a 16.8% premium to NAV.
- Syncona (SYNC) has announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35m commitment in a Series A financing of which Syncona has committed £34.0m with a further £1m being contributed by UCL Technology Fund. Syncona will have a 69.3 per cent stake in the business, with the first tranche of the Series A commitment of £8.3m paid in March 2019. Quell has been established with the aim of developing engineered T regulatory (Treg) cell therapies.
- We also covered Residential Secure Income’s interim results, a £200m raise by PRS REIT and a £64m conditional commitment secured by GCP Infrastructure.
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated